Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects new combinations of treatment will have
this disease. New promising treatment strategies will be added to this study as they are
available to be compared against the standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Janssen, LP Karyopharm Therapeutics Inc Roche Pharma AG